Biocon to give more data on itolizumab after use in covid-19 treatment rejected3 min read . Updated: 27 Jul 2020, 07:33 PM IST
Biocon said that the drug has been used on nearly 1,000 patients across the country and generated good outcome data, and the company also announced plans to conduct a 200-patient, pan-India Phase 4 trial across 10-15 hospitals
Biocon Ltd will provide the National Task Force for covid-19 a large sample of real world data on its novel biological drug itolizumab for treatment of cytokine storm in severe patients after its initial 30-patient trial failed to convince the committee members to include the drug in its clinical management guidelines.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more